Clinical Trials Logo
  1. Home
  2. Tobacco Smoking
  3. NCT05505630

The Effects of Sedatives on Tobacco Use Disorder Version 2 — SED-TUD2  

Tobacco Smoking Clinical Trial

Official title:
The Effects of Sedatives on Tobacco Use Disorder Version 2

Clinical Trial Summary

Double-blind, placebo-controlled, randomized mechanistic clinical trial to test an intravenous dose of either ketamine, midazolam, dexmedetomidine, or a placebo (saline) on cigarette smoking behavior, craving, and neural effects.

Clinical Trial Description

This double-blind, placebo-controlled, randomized mechanistic clinical trial will test non-treatment seeking smokers with an intravenous infusion of ketamine (0.71 mg/kg), midazolam (0.025 mg/kg), dexmedetomidine (0.025 mg/kg), or placebo, at least 2 weeks apart. Participants will complete 7-day ecological momentary assessment (EMA) of daily craving, withdrawal, and smoking behavior before and after each infusion. They will be asked to abstain from tobacco/nicotine for twenty-four hours post-infusion to induce withdrawal symptoms and return to the lab the following day to complete measures of craving, withdrawal, an MRI scan, and smoking latency. After this study visit, participants will be allowed to smoke as usual for the rest of the EMA diary period. Physical and subjective effects and adverse effects will be closely monitored throughout. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05505630
Study type Interventional
Source Wake Forest University Health Sciences
Contact Merideth Addicott
Phone 336-716-7792
Email maddicot@wakeforest.edu
Status Recruiting
Phase Early Phase 1
Start date January 31, 2023
Completion date December 2024
View Details
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05415371 - Persistent Poverty Counties Pregnant Women With Medicaid N/A
Recruiting NCT04038255 - Mindfulness Based Smoking Cessation Among Cancer Survivors Phase 4
Completed NCT04123041 - Characterize the Nicotine Uptake and Subjective Effects With Use of JUUL Electronic Nicotine Delivery Systems N/A
Completed NCT02735382 - EHR-Based and Fax-Based Referral to a Tobacco Quitline: A Comparative Study N/A
Completed NCT02139930 - Project 2: Strategies for Reducing Nicotine Content in Cigarettes N/A
Completed NCT04107779 - Changes in Biomarkers of Cigarette Smoke Exposure After Switching Either Exclusively or Partly to JUUL ENDS N/A
Completed NCT05037656 - Testing a School-Based E-cigarette, Tobacco, and Betel (Areca) Nut Use Prevention Curriculum for Guam Youths N/A
Completed NCT04200157 - Testing the Decoy Effect to Increase Tobacco Treatment Uptake
Enrolling by invitation NCT06042361 - Enhancing Equity in Smoke-free Housing N/A
Completed NCT02841683 - Pragmatic Randomised Controlled Trial Evaluating Effectiveness of a Smoking Cessation e- Intervention " Tabac Info Service " N/A
Completed NCT03151421 - Air Quality Feedback to Reduce Second-hand Smoke (SHS) Exposure in the Home N/A
Completed NCT04104152 - CSD190203: A Study to Determine Subject Puffing Patterns of an Electronic Nicotine Delivery System in an Ambulatory Setting N/A
Recruiting NCT05306158 - Dual Use Approach Bias Training for Nicotine Addiction N/A
Completed NCT04094363 - CSD190202: Study to Assess Elements of Abuse Liability for Two Electronic Nicotine Delivery Systems N/A
Completed NCT04143256 - Evaluating Selected Constituents in the Exhaled Breath Samples N/A
Completed NCT03553992 - An Extended Facebook Intervention for Young Sexual and Gender Minority Smokers N/A
Completed NCT05102786 - CSD210904: Study to Assess Actual Use of a Heated Tobacco Product With Four Non-Combusted Cigarette Variants in Current Adult Smokers
Terminated NCT04396847 - Laboratory Screening of Lorcaserin for Alcohol Use Disorder Phase 2
Completed NCT03694327 - Innovative Digital Therapeutic for Smoking Cessation N/A
Completed NCT05030194 - Comparing Nicotine Delivery, Subjective Effects, and Sensory Experiences of Tobacco Users Using Oral Nicotine Products and Electronic Cigarettes [ZYN Study] N/A